What do systematic reviews say?

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leukotriene receptor antagonist vs placebo

It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 2.1 [0.21, 21.39]
  1 study · 41 participants
  Very low

Leukotriene receptor antagonist vs placebo

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.68 [0.66, 4.28]
  1 study · 41 participants
  Very low

Leukotriene receptor antagonist vs usual care

The review found no eligible studies for this question.

• Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
  OR 0.5 [0.17, 1.46]
  2 studies · 1326 participants
  Low

Leukotriene receptor antagonist vs usual care

Leukotriene receptor antagonist showed no clear difference in adverse events compared with usual care (high certainty).

• Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
  OR 0.91 [0.63, 1.32]
  2 studies · 1326 participants
  High

Leukotriene receptor antagonist vs placebo

Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower time to resolution of first ulcer (days) compared with placebo; GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -3.95 [-4.38, -3.52]
  1 study · 40 participants
  GRADE not reported

Leukotriene receptor antagonist vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  The study reported equal drug-related adverse effects for those treated with montelukast and placebo.
  1 study · 40 participants
  GRADE not reported

Leukotriene receptor antagonist vs placebo

Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower total number of new lesions over 2-month treatment period compared with placebo; GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -3.90 [-4.55, -3.25]
  1 study · 40 participants
  GRADE not reported

Leukotriene receptor antagonist vs placebo

Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower pain (visual analogue scale) compared with placebo; GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -1.15 [-1.46, -0.84]
  1 study · 40 participants
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with montelukast (leukotriene receptor antagonist); GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -2.40 [-2.76, -2.04]
  1 study · 40 participants
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… showed no clear difference in total number of new lesions over 2-month treatment period compared with montelukast (leukotriene receptor antagonist); GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -0.30 [-0.90, 0.30]
  1 study · 40 participants
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  The study reported more drug-related adverse effects for those treated with prednisone than montelukast.
  1 study · 40 participants
  GRADE not reported

Montelukast vs placebo

• Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 131 participants
  Low

Montelukast vs Conventional treatment

• Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 63 participants
  Low

Montelukast vs Conventional treatment

The review found no eligible studies for this question.

• Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Montelukast vs Conventional treatment

The review found no eligible studies for this question.

• Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found